ABOUT THIS PODCAST
Antifungal therapeutic drug monitoring is a critical component of individualized, precision treatment for fungal infections and for antifungal stewardship. Antifungal therapeutic drug monitoring can help improve outcomes through minimizing toxicity associated with supratherapeutic drug levels and prevent treatment failure from subtherapeutic levels. Also, in vitro studies have shown that suboptimal drug levels can lead to antifungal resistance, supporting therapeutic drug monitoring's potential role in preventing the emergence of antifungal-resistant organisms. This episode podcast, we discuss outcome data when antifungal TDM is used, role of antifungal TDM with isavuconazole and echinocandins, TDM in outpatient settings, and other controversies. We will also highlight the recent antifungal TDM insights published by SIDP.
REFERENCES/RESOURCES
- Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021 | Open Forum Infectious Diseases | Oxford Academic (oup.com)
- Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections | Infectious Diseases and Therapy (springer.com)
- Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists - McCreary - 2023 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
- Antifungal Therapeutic Drug Monitoring Practices: Results of an Emerging Infections Network Survey | Open Forum Infectious Diseases | Oxford Academic (oup.com)
- 5 Things to Know About Antifungal Therapeutic Drug Monitoring (medscape.com)
